From: Attrition in longitudinal randomized controlled trials: home visits make a difference
ROUTINE F/U, N=187 | HOME F/U, N=61 | |||||
---|---|---|---|---|---|---|
% unless otherwise indicated | % unless otherwise indicated | |||||
ALL N=187 | LOW MAP N=97 (52%) | HIGH MAP N=90 (48%) | ALL N=61 | LOW MAP N=27 (44%) | HIGH MAP N=34 (56%) | |
Demographic | ||||||
Age, mean years (SD) | 65.2 (9.3) | 65.2 (10.1) | 65.3 (8.4) | 67.7 (9.5) | 70.0 (9.5) | 65.9 (9.3) |
75 years and older | 13.9 | 16.5 | 11.1 | 29.5 | 40.7 | 20.6 |
Male | 78.6 | 78.3 | 78.9 | 83.6 | 78.8 | 88.2 |
Caucasian | 95.6 | 94.6 | 96.6 | 98.3 | 96.3 | 100 |
College education or higher | 48.4 | 50.5 | 46.0 | 44.8 | 41.7 | 47.1 |
Married | 73.3 | 73.2 | 73.3 | 77.0 | 63.0 | 88.2* |
Cardiac and Neurologic History | ||||||
Cardiac symptom duration, mean years (SD) | 5.0 (7.1) | 5.3 (7.6) | 4.7 (6.7) | 5.7 (8.6) | 5.6 (8.4) | 5.9 (8.8) |
Current and former smokers | 72.7 | 71.1 | 74.4 | 78.7 | 81.5 | 76.5 |
Canadian cardiovascular class | ||||||
I | 18.7 | 19.6 | 17.8 | 13.1 | 14.8 | 11.8 |
II | 22.5 | 24.7 | 20.0 | 27.9 | 25.9 | 29.4 |
III | 12.3 | 11.3 | 13.3 | 16.4 | 29.6 | 5.9 |
IV | 27.8 | 30.9 | 24.4 | 16.4 | 14.8 | 17.7 |
Ejection Fraction, mean (SD) | 48.5 (12.1) | 49.3 (12.1) | 47.6 (12.2) | 47.4 (13.9) | 47.2 (15.1) | 47.6 (13.0) |
Left main disease | 13.9 | 14.4 | 13.3 | 11.5 | 22.2 | 2.9* |
Previous MI | 42.3 | 36.1 | 48.9 | 44.3 | 44.4 | 44.1 |
Congestive heart failure | 10.7 | 10.3 | 11.1 | 11.5 | 14.8 | 8.8 |
COPD/Asthma | 10.7 | 6.2 | 15.6* | 6.6 | 7.4 | 5.8 |
Peripheral vascular disease | 21.9 | 23.7 | 20.0 | 16.4 | 22.2 | 11.8 |
CVA | 11.8 | 8.3 | 15.6 | 8.2 | 7.4 | 8.8 |
Charlson Comorbidity Score | ||||||
0-1 | 58.8 | 58.8 | 58.9 | 54.1 | 48.1 | 58.8 |
2-3 | 27.8 | 27.8 | 27.8 | 36.1 | 44.4 | 29.4 |
≥ 4 | 13.4 | 13.4 | 13.3 | 9.8 | 7.4 | 11.8 |
Hypertension | 49.2 | 43.3 | 55.6 | 59.0 | 59.3 | 58.8 |
Dialysis | 1.6 | 2.1 | 1.1 | 0 | 0 | 0 |
Renal dysfunction | 5.9 | 6.2 | 5.6 | 4.9 | 3.7 | 5.9 |
Diabetes | 20.3 | 23.7 | 16.7 | 19.7 | 18.5 | 20.6 |
End organ damage | 44.7 | 43.5 | 46.7 | 33.3 | 40.0 | 28.6 |
Medications | ||||||
Diuretics | 16.0 | 16.5 | 15.6 | 27.9 | 33.3 | 23.5 |
Calcium channel blockers | 62.6 | 60.8 | 64.4 | 63.9 | 55.6 | 70.6 |
Nitrates | 55.1 | 60.8 | 48.9 | 52.5 | 70.4 | 38.2* |
Beta blockers | 57.8 | 55.7 | 60.0 | 52.5 | 48.2 | 55.9 |
Ace inhibitors | 16.6 | 17.5 | 15.6 | 16.4 | 22.2 | 11.8 |
Neurocognitive tests | ||||||
Ammons IQ Test, mean (SD) | 106.6 (14.4) | 107.2 (15.5) | 106.0 (13.3) | 102.3 (12.2) | 100.2 (10.5) | 103.9 (13.2) |
Linguistic Function | ||||||
Boston Naming Test, median (range) | 26.0 (8–30) | 26.0 (8–30) | 26.0 (11–30) | 25 (9–30) | 25 (12–30) | 25 (9–30) |
Controlled Word Association, mean (SD) | 38.4 (13.4) | 38.4 (13.5) | 38.4 (13.3) | 35.1(12.6) | 34.2 (11.4) | 35.7 (13.5) |
Memory | ||||||
Benton Visual Recall, mean (SD) | 5.2 (2.2) | 5.3 (2.1) | 5.1 (2.3) | 4.6 (2.2) | 5.0 (1.9) | 4.3 (2.4) |
Benton Recognition, median (range) | 8 (3–10) | 8 (3–10) | 8 (4–10) | 7.5 (0–10) | 7 (3–10) | 8 (0–10) |
Mattis-Kovner Recall, mean (SD) | 10.7 (3.4) | 10.9 (3.4) | 10.6 (3.4) | 9.9 (3.6) | 9.6 (4.0) | 10.3 (3.2) |
Mattis-Kovner, mean (SD) | 2.7 (0–3.9) | 2.7 (0–3.9) | 2.7 (0–3.9) | 2.6 (1.2-3.9) | 2.4 (1.3-3.9) | 2.7 (1.2-3.9) |
Recognition, median (range) | ||||||
Psychomotor function | ||||||
Trails A, median (range) | 40 (15–162) | 38.5 (15–162) | 41 (20–141) | 39 (17–217) | 39 (19–100) | 41.5 (17–217) |
Trails B, median (range) | 86 (32–350) | 85.0 (32–350) | 89.5 (42–320) | 104.5 (38–405) | 117 (42–405) | 92 (38–309) |
Digit Symbol, mean (SD) | 42.1 (12.3) | 42.7 (13.6) | 41.5 (10.7) | 38.2 (11.9) | 34.7 (12.3) | 41.2 (10.9)* |
Digit Span, mean (SD) | 14.7 (4.1) | 15.2 (4.0) | 14.1 (4.1) | 14.0 (3.7) | 13.3 (3.5) | 14.5 (3.8) |
Finger Tapping Dominant, mean (SD) | 47.1 (10.6) | 47.0 (10.6) | 47.2 (10.6) | 44.2 (8.4) | 45.0 (8.9) | 43.5 (8.1) |
Finger Tapping Non-dominant, mean (SD) | 42.5 (8.9) | 42.1 (9.2) | 43.1 (8.7) | 40.7 (8.1) | 42.0 (8.0) | 39.6 (8.2) |